Immupharma (IMM)

 

Latest News

Grant of Options

RNS Number: 4907X Immupharma PLC 24 November 2017 24 NOVEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinar...

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

All News

DateHeadlineSource
05-06-13Holding(s) in CompanyRNS
23-05-13Result of AGMRNS
21-05-13ImmuPharma agrees £50 financingStockMarketWire
21-05-13?50M Financing Facility - Darwin StrategicRNS
22-04-13Posting of Annual Report and AGM NoticeRNS
09-04-13ImmuPharma losses riseStockMarketWire
09-04-13Preliminary ResultsRNS
28-02-13ImmuPharma starts trading on Stuttgart ExchangeStockMarketWire
28-02-13ImmuPharma Commences Trading on Stuttgart ExchangeRNS
28-01-13Director Deals - ImmuPharma PLC (IMM)StockMarketWire
28-01-13Director/PDMR Shareholding - ReplacementRNS
28-01-13Director Deals - ImmuPharma PLC (IMM)StockMarketWire
28-01-13Director/PDMR ShareholdingRNS
28-01-13CNRS confirms Lupuzor's effectivenessStockMarketWire
28-01-13CNRS Confirms Lupuzor's (TM) EffectivenessRNS
15-11-12Lupuzor PresentationRNS
05-11-12Lupuzor PresentationRNS
03-10-12Notification of Major Interest in SharesRNS
26-09-12Markets: Global growth fears hit FTSE 100 on WednesdayInteractive Investor
26-09-12First Cancer Patients in New Trial Begin DosingRNS
26-09-12Interim ResultsRNS
26-09-12What's in store today...Interactive Investor
21-09-12The week ahead...Interactive Investor
20-09-12Notification of Interim ResultsRNS
07-09-12Rodman and Renshaw ConferenceRNS
17-08-12Notification of Major Interest in SharesRNS
11-07-12Voted Best Medical Research & Development CompanyRNS
09-07-12New Corporate WebsiteRNS
03-07-12Appointment of Joint BrokerRNS
23-05-12Annual General Meeting: 2012RNS
17-04-12Posting of Annual Report and AGM NoticeRNS
02-04-12Hybridan's Small Cap WrapHybridan
27-03-12Preliminary ResultsRNS
27-03-12What's in store today...Interactive Investor
23-03-12The week ahead...Interactive Investor
20-03-12Notification of Full Year ResultsRNS
29-02-12Appoints Head of Investor RelationsRNS
24-01-12Director's DealingsRNS
14-11-11Hybridan's Small Cap WrapHybridan
30-10-11Hybridan's Small Cap WrapHybridan

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account